DANBURY, Conn., Aug. 22 /PRNewswire-FirstCall/ -- Biodel, Inc. (Nasdaq: BIOD) today announced the addition of Ralf Rosskamp, M.D., to its Scientific Advisory Board (SAB).
Dr. Rosskamp was previously the Executive Vice President of Research and Development at Kos Pharmaceuticals, where he managed all research and development activities until Kos was acquired by Abbott Laboratories. Dr. Rosskamp's accomplishments at Kos include building an integrated research and development organization, globally expanding Kos's clinical research organization and assisting in the approval of four supplemental new drug applications.
"We are extremely honored to have Dr. Rosskamp join our SAB," said Dr. Solomon Steiner, CEO and Chairman of Biodel. "Dr. Rosskamp played an integral role in bringing insulin analogs to the market. His wealth of knowledge and clinical experience in the field of endocrinology will significantly contribute to the development of VIAject(TM), VIAtab(TM) and our two osteoporosis product candidates."
"I am delighted to join Biodel's SAB, especially at such an exciting time for the Company," said Dr. Rosskamp. "Biodel has created an innovative, injectable human insulin for diabetics and has made great progress in the clinical development of VIAject(TM). I look forward to collaborating with the Biodel team in their efforts to bring safer and more effective treatments to the diabetic patient population."
Prior to joining Kos, Dr. Rosskamp held prominent positions for
thirteen years at Aventis Pharmaceuticals, a lead-developer of
endocrinology products. At Aventis, Dr. Rosskamp was responsible for
achieving FDA/EMEA approval of Lantus(R), the best-selling basal insulin
analog and coordinating the clinical trials for Apidra(R), a rapid-acting
insulin analog. In addition, Dr. Rosskamp managed the approval process for
Actonel(R) Once-a-Week, which prevents and treats post-menopausal
osteoporosis, and aided in completing the Phase III study
|SOURCE Biodel, Inc.|
Copyright©2007 PR Newswire.
All rights reserved